PDT Partners’s XBiotech XBIT Stock Holding History

PDT Partners’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16,976	Closed	-$96K	–	1121
2022 Q2	$96K	Buy	16,976 +3,912	+30%	+$26.3K	0.01%	886
2022 Q1	$113K	Buy	+13,064	New	+$131K	0.01%	859

Other funds holding XBIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PDT Partners's XBIT Position: Q3 2022 in Review

PDT Partners sold out of XBiotech (XBIT) in Q3 2022, closing a stake of 16,976 shares — an estimated $96K sold.

PDT Partners first reported a position in XBIT in Q1 2022 and held it in 2 quarters. The position peaked at $113K in Q1 2022. 45 funds tracked by Wall St. Rank hold XBIT as of Q3 2022.

PDT Partners reported no remaining XBiotech position as of Q3 2022 after selling out during the quarter.
PDT Partners sold 16,976 XBiotech shares in Q3 2022, an estimated $96K.
PDT Partners first reported a position in XBiotech in Q1 2022 and held it in 2 quarters.
PDT Partners's XBiotech position peaked at $113K in Q1 2022.
45 funds tracked by Wall St. Rank held XBiotech as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.